Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders
Pengfei Xu, Pei Shen, Bin Yu, et al.
European Journal of Medicinal Chemistry (2020) Vol. 192, pp. 112155-112155
Closed Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1139
A Comprehensive Overview of Globally Approved JAK Inhibitors
Ahmed M. Shawky, Faisal A. Almalki, Ashraf N. Abdalla, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 1001-1001
Open Access | Times Cited: 200
A review: FDA-approved fluorine-containing small molecules from 2015 to 2022
Negar Sheikhi, Maryam Bahraminejad, Mina Saeedi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115758-115758
Closed Access | Times Cited: 47
Advances in the Regulation of Macrophage Polarization by Mesenchymal Stem Cells and Implications for ALI/ARDS Treatment
Chang Liu, Kun Xiao, Lixin Xie
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 57
The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies
George Mihai Nițulescu, Gheorghe Stancov, Oana Cristina Șeremet, et al.
Molecules (2023) Vol. 28, Iss. 14, pp. 5359-5359
Open Access | Times Cited: 35
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 14
Research progress of targeted therapy regulating Th17/Treg balance in bone immune diseases
Xiaoxia Wang, Bai Sun, Yujie Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 10
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
Przemysław Kotyla, Małgorzata Engelmann, Joanna Giemza-Stokłosa, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2449-2449
Open Access | Times Cited: 47
A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine–related JAK-STAT signal
Chengjuan Chen, Yuan Yin, Gaona Shi, et al.
Science Advances (2022) Vol. 8, Iss. 33
Open Access | Times Cited: 37
Selective JAK1 inhibitors for the treatment of inflammatory bowel disease
Ole Haagen Nielsen, Theresa Louise Boye, John Gubatan, et al.
Pharmacology & Therapeutics (2023) Vol. 245, pp. 108402-108402
Open Access | Times Cited: 22
Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives
Kamonpan Sanachai, Thitinan Aiebchun, Panupong Mahalapbutr, et al.
RSC Medicinal Chemistry (2021) Vol. 12, Iss. 3, pp. 430-438
Open Access | Times Cited: 33
Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases
Pei Shen, Yezhi Wang, Xiangxiang Jia, et al.
European Journal of Medicinal Chemistry (2022) Vol. 239, pp. 114551-114551
Closed Access | Times Cited: 27
Co-Delivery of Loxoprofen and Tofacitinib by Photothermal Microneedles for Rheumatoid Arthritis Treatment
Yi Lu, Ting Xiao, Rongrong Lai, et al.
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1500-1500
Open Access | Times Cited: 16
JAK2 inhibitor ameliorates the progression of experimental autoimmune myasthenia gravis and balances Th17/Treg cells via regulating the JAK2/STAT3-AKT/mTOR signaling pathway
Yaru Lu, Qian Ma, Lu Yu, et al.
International Immunopharmacology (2023) Vol. 115, pp. 109693-109693
Closed Access | Times Cited: 15
Fluorinated azoles as effective weapons in fight against methicillin-resistance staphylococcus aureus (MRSA) and its SAR studies
Xuanming Zhao, Rameshwari Verma, M. B. Sridhara, et al.
Bioorganic Chemistry (2023) Vol. 143, pp. 106975-106975
Closed Access | Times Cited: 14
Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
Przemysław Kotyla, Md Asiful Islam, Małgorzata Engelmann
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 19, pp. 7390-7390
Open Access | Times Cited: 39
Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19
Magdalena Massalska, Włodzimierz Maśliński, Marzena Ciechomska
Cells (2020) Vol. 9, Iss. 8, pp. 1876-1876
Open Access | Times Cited: 35
Recent development of BTK-based dual inhibitors in the treatment of cancers
Fansheng Ran, Yun Liu, Zhongyuan Xu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 233, pp. 114232-114232
Closed Access | Times Cited: 21
Advances in Mesenchymal stem cells regulating macrophage polarization and treatment of sepsis-induced liver injury
Yuhao Chen, Lihong Yang, Xihong Li
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
The macrophage polarization by miRNAs and its potential role in the treatment of tumor and inflammation (Review)
Chaozhe Wang, Xidi Wang, Danfeng Zhang, et al.
Oncology Reports (2023) Vol. 50, Iss. 4
Open Access | Times Cited: 11
Identification of Thieno[3,2-d]pyrimidine Derivatives as Potent and Selective Janus Kinase 1 Inhibitors
Younghoon Kim, Eunhye Jeon, Ho Sam Ahn, et al.
European Journal of Medicinal Chemistry (2025), pp. 117308-117308
Closed Access
FDA-Approved Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) Inhibitors for Managing Rheumatoid Arthritis: A Narrative Review of the Literature
Tejaswini Potlabathini, Mounica A Pothacamuri, Venkata Varshitha Bandi, et al.
Cureus (2024)
Open Access | Times Cited: 3
Synthesis and clinical application of small-molecule inhibitors of Janus kinase
Jingyi Zhang, Jinfeng Sun, Peng Nie, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115848-115848
Closed Access | Times Cited: 9
Discovery of C-5 Pyrazole-Substituted Pyrrolopyridine Derivatives as Potent and Selective Inhibitors for Janus Kinase 1
Jiajia Lang, You Lv, Boštjan Kobe, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 10, pp. 6725-6742
Closed Access | Times Cited: 8
Major signaling pathways and key mediators of macrophages in acute kidney injury (Review)
Ning Li, Jiale Chen, Pengtao Wang, et al.
Molecular Medicine Reports (2021) Vol. 23, Iss. 6
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top